Evidence map›Paper›PMID 32503473›Full record

ArticleBMC neurology2020

The effect of physical activity on cognition relative to APOE genotype (PAAD-2): study protocol for a phase II randomized control trial.

Kyoung Shin Park, Alexis B Ganesh, Nathaniel T Berry, Yashonda P Mobley, William B Karper, Jeffrey D Labban, Christopher N Wahlheim, Tomika M Williams, Laurie Wideman, Jennifer L Etnier

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03876314 (The Effect of Physical Activity on Cognition Relative to APOE Genotype), which is not on this map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03876314 nacompletednot on this map

The Effect of Physical Activity on Cognition Relative to APOE Genotype (PAAD-2)

TypeinterventionalSponsorUniversity of North Carolina, GreensboroRan2019 to 2024Enrolled180ConditionsHealthy, Dementia, Alzheimer Disease, Physical ActivityArmsPhysical Activity Condition
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Kyoung Shin ParkDepartment of Kinesiology, University of North Carolina at Greensboro, Greensboro, NC, 27402, USA.
Alexis B GaneshDepartment of Kinesiology, University of North Carolina at Greensboro, Greensboro, NC, 27402, USA.
Nathaniel T BerryUnder Armour, Baltimore, MD, 21209, USA.
Yashonda P MobleyDepartment of Kinesiology, University of North Carolina at Greensboro, Greensboro, NC, 27402, USA.
William B KarperDepartment of Kinesiology, University of North Carolina at Greensboro, Greensboro, NC, 27402, USA.
Jeffrey D LabbanDepartment of Kinesiology, University of North Carolina at Greensboro, Greensboro, NC, 27402, USA.
Christopher N WahlheimDepartment of Psychology, University of North Carolina at Greensboro, Greensboro, NC, 27402, USA.
Tomika M WilliamsDepartment of Advanced Nursing Practice and Education, East Carolina University, Greenville, NC, 27858, USA.
Laurie WidemanDepartment of Kinesiology, University of North Carolina at Greensboro, Greensboro, NC, 27402, USA.
Jennifer L EtnierDepartment of Kinesiology, University of North Carolina at Greensboro, Greensboro, NC, 27402, USA. jletnier@uncg.edu.
University of North Carolina at Greensboro · USEast Carolina University · USUnder Armour (United States) · US

Funding

The effect of physical activity on cognition relative to APOE genotype (PAAD-II)R01AG058919 · NIA · UNIVERSITY OF NORTH CAROLINA GREENSBORO · PI ETNIER, JENNIFER L · 2018 to 2022
$3.6M
NIA NIH HHS R01 AG058919NIA NIH HHS R01AG058919
6 · The paper itself

Abstract

backgroundBy 2050, the prevalence of Alzheimer's disease (AD) in the United States is predicted to reach 13.8 million. Despite worldwide research efforts, a cure for AD has not been identified. Thus, it is critical to identify preventive strategies that can reduce the risk of or delay the onset of AD. Physical activity (PA) has potential in this regard. This randomized clinical trial aims to (a) test the causal relationship between PA and AD-associated cognitive function for persons with a family history of AD (FH+), (b) determine the moderating role of apolipoprotein epsilon 4 (APOE4) carrier status on cognition, and (c) assess cerebral structure, cerebral function, and putative biomarkers as mediators of the effects of PA on cognition.

methodsWe are recruiting cognitively normal, middle aged (40-65 years) sedentary adults with FH+. Participants are randomly assigned to a 12-month PA intervention for 3 days/week or to a control group maintaining their normal lifestyle. Saliva samples are taken at pre-test to determine APOE genotype. At pre-, mid-, and post-tests, participants complete a series of cognitive tests to assess information-processing speed, verbal and visual episodic memory, constructional praxis, mnemonic discrimination, and higher-order executive functions. At pre- and post-tests, brain imaging and blood biomarkers are assessed. DISCUSSION: We hypothesize that 1) the PA group will demonstrate improved cognition compared with controls; 2) PA-derived cognitive changes will be moderated by APOE4 status; and 3) PA-induced changes in neural and blood biomarkers will contribute to cognitive changes and differ as a function of APOE4 status. Our results may provide important insights into the potential of PA to preserve neurocognitive function in people with a heightened risk of AD due to FH+ and as moderated by APOE4 status. By using sophisticated analytic techniques to assess APOE as a moderator and neurobiological mechanisms as mediators across trajectories of cognitive change in response to PA, we will advance our understanding of the potential of PA in protecting against AD.

trial registrationClinicalTrials.gov NCT03876314. Registered March 15, 2019.

Indexed as

Alzheimer DiseaseApolipoproteins ECognitionExerciseExercise TherapyAdultAgedBrainClinical Trials, Phase II as TopicGenotypeHumansMiddle AgedRandomized Controlled Trials as TopicApolipoproteins EAlzheimer’s diseaseApolipoproteinBDNFDementiaEpisodic memoryExecutive functionExercise interventionFluid intelligenceMRI

Identifiers

PMID32503473
PMCPMC7274941
OpenAlexW3033453307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.